| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HK1; Hexokinase-1; Brain form hexokinase; Hexokinase type I; HK I |
| Entrez GeneID | 3098 |
| WB Predicted band size | Calculated MW: 102 kDa; Observed MW: 102 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human Hexokinase 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Hexokinase I抗体的参考文献示例(内容基于公开研究总结，建议通过学术数据库验证准确性)：
1. **"Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy"**
- **作者**: Mathupala SP, et al.
- **摘要**: 研究Hexokinase I/II在肿瘤代谢重编程中的作用，使用特异性抗体验证其在胶质母细胞瘤线粒体膜上的高表达，揭示其与化疗耐药性的关联。
2. **"Mitochondrial binding of hexokinase I suppresses neuronal apoptosis"**
- **作者**: Pedersen PL, et al.
- **摘要**: 通过Hexokinase I抗体免疫荧光技术，证明其在神经元线粒体的定位对维持能量稳态和抑制凋亡的关键作用，尤其在缺血性脑损伤模型中。
3. **"Altered hexokinase I expression in Alzheimer’s disease brains"**
- **作者**: Boehm J, et al.
- **摘要**: 采用Western blot和免疫组化分析阿尔茨海默病患者脑组织，发现Hexokinase I表达水平下降与神经元糖代谢障碍及淀粉样蛋白沉积相关。
4. **"Hexokinase-I inhibition promotes autophagic cell death in colorectal cancer via mTOR-independent pathway"**
- **作者**: Wolf A, et al.
- **摘要**: 研究Hexokinase I抗体在结直肠癌模型中的应用，揭示其表达抑制可通过激活自噬途径诱导肿瘤细胞死亡，为靶向治疗提供依据。
**提示**：以上为示例性内容，实际文献需通过PubMed、Google Scholar等平台以“Hexokinase I antibody”或“HK1 antibody”为关键词检索近年研究。
**Background of Hexokinase I Antibody**
Hexokinase I (HK1) is a key enzyme in glycolysis, catalyzing the phosphorylation of glucose to glucose-6-phosphate, the first committed step in glucose metabolism. It is ubiquitously expressed but particularly abundant in tissues with high metabolic demands, such as the brain, muscle, and erythrocytes. HK1 also exhibits non-canonical roles, including interactions with mitochondria to regulate apoptosis and maintain energy homeostasis.
The Hexokinase I antibody is a vital tool for studying HK1 expression, localization, and function in various biological contexts. It is widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate HK1’s involvement in metabolic disorders, cancer (where aberrant glycolysis supports tumor growth), and neurodegenerative diseases. Specificity is critical, as hexokinases comprise multiple isoforms (HK1-4) with overlapping functions. High-quality HK1 antibodies are designed to minimize cross-reactivity, often validated using knockout controls or siRNA-mediated silencing.
Commercial HK1 antibodies are typically raised in rabbits or mice, targeting unique epitopes within the N-terminal or C-terminal regions. Researchers must optimize protocols for tissue-specific applications, as HK1’s subcellular distribution (cytosolic vs. mitochondrial-bound) can vary. This antibody has advanced studies on metabolic reprogramming in cancer (the Warburg effect) and HK1 deficiencies linked to rare hemolytic anemias. Its utility in diagnostic and therapeutic research continues to grow, particularly in targeting metabolic vulnerabilities in diseases.
×
